This result could be partially explained by the diverse biomarker profile of patients recruited in the study (seven RET fusions, four FGFR mutations, and one FGFR3 fusion) and the biological complexity of lung adenocarcinoma, which makes up the majority of the NSCLC cohort. This evidence concerns the gene RET and non-small cell lung carcinoma.